Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

IRIS-RA

- PMLiVE

Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

- PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

The companies will focus on inflammatory diseases that have been historically difficult to treat

- PMLiVE

Johnson & Johnson’s Imaavy granted FDA approval for rare autoimmune disease gMG

Myasthenia gravis affects an estimated 700,000 people worldwide

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease

The chronic autoimmune disease affects approximately four million people globally

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis

The severity of the rare autoimmune disease is heightened in paediatric patients

- PMLiVE

Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn

The agreement will see Mestag use its platform designed to model the pathogenic role of fibroblasts

- PMLiVE

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Johnson & Johnson shares positive phase 3 results for nipocalimab in myasthenia gravis

The rare autoimmune disease is estimated to affect around 700,000 people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links